SOURCE: AspenBio Pharma, Inc.

September 03, 2009 12:30 ET

AspenBio Pharma to Present at the Rodman & Renshaw Annual Global Investment Conference

Management to Discuss AppyScore™, the First Blood-Based Test to Aid in the Diagnosis of Human Appendicitis

CASTLE ROCK, CO--(Marketwire - September 3, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has been invited to present at the Rodman & Renshaw Annual Global Investment Conference to be held at the New York Palace Hotel on September 9-11, 2009.

Company management is scheduled to present on Wednesday, September 9, 2009 at 12:30 p.m. Eastern time, with one-on-one meetings held throughout the day.

Management will discuss the company's progress, including its recently filed Premarket Notification 510(k) with the U.S. Food and Drug Administration ("FDA") for AppyScore, the first blood-based test designed to rule out the diagnosis of human appendicitis.

The test is expected to be used in combination with other modalities currently used in diagnosing appendicitis. AppyScore's target market is the 5.6 million people who enter hospital Emergency Departments annually and have blood and associated lab work performed to aid in the diagnosis of abdominal pain.

AspenBio is also advancing a new class of drugs that replace natural reproductive hormones for animals of economic importance. The company has a development and marketing agreement with Novartis Animal Health (NYSE: NVS) for the bovine species.

Leading the presentation will be the company's executive chairman and CEO, Daryl Faulkner, who was previously president, CEO and board member of Digene Corp., a Nasdaq-traded company prior to its acquisition by Qiagen.

For more information about the conference or to schedule a one-on-one meeting with the company, contact your Rodman & Renshaw representative or the conference desk at +1-212-356-0500.

About Rodman & Renshaw

Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.

About AspenBio Pharma, Inc.

AspenBio Pharma, Inc. (NASDAQ: APPY) is an emerging bio-science company dedicated to the discovery, development and commercialization of novel products that address unmet diagnostic and therapeutic needs in both human and animal health. The company's AppyScore blood-based test addresses the difficult challenge of diagnosing human appendicitis in the hospital emergency department. The company is also advancing unique therapeutic proteins designed to improve reproduction in non-companion animals of economic importance. For more information, go to

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the company's actual results to vary materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the company believes are appropriate in the circumstances. Meaningful factors, which could cause actual results to differ from expectations, many of which are beyond the control of the company, include, but are not limited to, our ability to successfully complete the clinical trial data assessments required for FDA submission, obtain FDA approval for, cost effectively manufacture and generate revenues from, the appendicitis test in development, as well as the animal products and other new products developed by the company, and our ability to retain the scientific management team to advance the products in development, execute agreements to provide the company with rights to meet its objectives, overcome adverse changes in market conditions and the regulatory environment, and obtain and enforce intellectual property rights. The company does not intend (and is not obligated) to update publicly any such forward-looking statements. For other factors that may impact such forward-looking statements, reference is made to our annual and quarterly reports filed with the Securities and Exchange Commission.

Contact Information

  • Company Contact:
    Gregory Pusey
    Vice Chairman
    AspenBio Pharma, Inc.
    Tel 303-722-4008

    Investor Relations:
    Liolios Group, Inc.
    Ron Both or Geoffrey Plank
    Tel 949-574-3860
    Email: Email Contact